NCT03853421View on ClinicalTrials.gov

Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 6, 2019

Primary Completion Date

May 6, 2019

Study Completion Date

May 6, 2019

Conditions

Safety and Tolerability

Interventions

DRUG

Sevuparin

The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.

Trial Locations (1)

33014

Clinical Pharmacology of Miami (CPMI), Miami